Definium Therapeutics, Inc.
DFTX
주식 순위
#3498
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
주가
$36.10
시가총액
$4.85B
변동 (1일)
1.71%
변동 (1년)
240.58%
국가
US
거래 Definium Therapeutics, Inc. (DFTX)
카테고리
Healthcare
Definium Therapeutics, Inc. (DFTX)의 주가 이력
최고 종가: $10.57 (2024-04-01 기준)
최저 종가: $4.87 (2020-03-01 기준)
최저 종가: $4.87 (2020-03-01 기준)
Definium Therapeutics, Inc.의 주가 이력 (2020 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2024 | 205.04% |
| 2023 | 33.53% |
| 2022 | -89.94% |
| 2021 | -40.17% |
| 2020 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $536.74 | 25.87% |
US
|
|
| $227.23 | 746.28% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $881.75 | 8.30% |
NL
|
